OMEGA-3-CARBOXYLIC ACIDS

Summary

Omega-3-Carboxylic Acids (CHEMBL3137327) is an approved unknown; indicated across 2 conditions including hypertriglyceridemia and crohn disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• Indications: 2 conditions
• Clinical trials: 6
• Chemistry: 2750 Da · C181H286O18

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3137327
Name	OMEGA-3-CARBOXYLIC ACIDS
Type	Unknown
Max phase	4
FDA approved	no
PubChem CID	76322221
Molecular formula	C181H286O18
Molecular weight	2750
InChIKey	QIQSYARFOIKJJR-LUTWCBITSA-N

SMILES: CCCCC/C=C\C/C=C\CCCCCCCC(=O)O.CCCCC/C=C\C/C=C\C/C=C\CCCCC(=O)O.CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O.CC/C=C\C/C=C\C/C=C\CCCCCCCC(=O)O.CC/C=C\C/C=C\C/C=C\C/C=C\CCCCCCC(=O)O.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)O.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O

IUPAC name: (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid;(4Z,7Z,10Z,13Z,16Z)-docosa-4,7,10,13,16-pentaenoic acid;(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoic acid;(6Z,9Z,12Z,15Z,18Z)-henicosa-6,9,12,15,18-pentaenoic acid;(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoic acid;(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoic acid;(9Z,12Z)-octadeca-9,12-dienoic acid;(6Z,9Z,12Z)-octadeca-6,9,12-trienoic acid;(9Z,12Z,15Z)-octadeca-9,12,15-trienoic acid

Also known as: Epanova, Omega-3 carboxylic acid

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hypertriglyceridemia	3	MONDO:0005347	EFO:0004211
Crohn disease	3	MONDO:0005011	EFO:0000384

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2	2
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00613197	PHASE3	COMPLETED	EPANOVA in Crohn’s Disease, Study 1
NCT02009865	PHASE3	COMPLETED	Epanova® for Lowering Very High Triglycerides II (EVOLVE II)
NCT01208961	PHASE2	COMPLETED	Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation
NCT02354976	PHASE2	COMPLETED	A Double-blind Randomized Placebo-controlled Study Comparing Epanova and Fenofibrate on Liver Fat in Overweight Subjects.
NCT02189252	PHASE1	COMPLETED	An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis
NCT03574142	PHASE1	COMPLETED	A Ph 1 Study of Epanova® in Healthy Chineses

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).